ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Madrid, MD, ESP:

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 108 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Madrid, Spain and 49 other locations

together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...

Active, not recruiting
Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 27 other locations

objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...

Enrolling
CLL
Drug: Zanubrutinib
Drug: Sonrotoclax

Phase 3

BeiGene
BeiGene

Madrid, Spain and 111 other locations

patient populations.CAP-100 is expected to prevent the migration of leukemia cells to and their survival in lymphoid niches as well as to el...

Enrolling
Lymphocytic Leukemia, Chronic
SLL
Drug: CAP-100

Phase 1

Catapult Therapeutics

Madrid, Spain and 5 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 67 other locations

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Madrid, Madrid, Comunidad De, Spain and 107 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Madrid, Spain and 130 other locations

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...

Active, not recruiting
Chronic Lymphocytic Leukemia
Hypogammaglobulinemia
Biological: Panzyga
Other: Placebo

Phase 3

Octapharma

Madrid, Spain and 83 other locations

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Nemtabrutinib
Drug: Acalabrutinib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Pozuelo de Alarcon, Madrid, Spain and 143 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems